<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2764</journal-id><journal-id journal-id-type="pmc-domain">vaccines</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7159032</article-id><article-id pub-id-type="pmcid-ver">PMC7159032.1</article-id><article-id pub-id-type="pmcaid">7159032</article-id><article-id pub-id-type="pmcaiid">7159032</article-id><article-id pub-id-type="pmid">32024238</article-id><article-id pub-id-type="doi">10.3390/vaccines8010063</article-id><article-id pub-id-type="publisher-id">vaccines-08-00063</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>A Review on Dengue Vaccine Development</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Deng</surname><given-names initials="SQ">Sheng-Qun</given-names></name><xref ref-type="aff" rid="af1-vaccines-08-00063">1</xref><xref ref-type="author-notes" rid="fn1-vaccines-08-00063">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="X">Xian</given-names></name><xref ref-type="aff" rid="af1-vaccines-08-00063">1</xref><xref ref-type="author-notes" rid="fn1-vaccines-08-00063">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wei</surname><given-names initials="Y">Yong</given-names></name><xref ref-type="aff" rid="af1-vaccines-08-00063">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="JT">Jia-Ting</given-names></name><xref ref-type="aff" rid="af1-vaccines-08-00063">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="XJ">Xiao-Jun</given-names></name><xref ref-type="aff" rid="af2-vaccines-08-00063">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9345-8218</contrib-id><name name-style="western"><surname>Peng</surname><given-names initials="HJ">Hong-Juan</given-names></name><xref ref-type="aff" rid="af1-vaccines-08-00063">1</xref><xref rid="c1-vaccines-08-00063" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-vaccines-08-00063"><label>1</label>Department of Pathogen Biology, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou 510515, China; <email>dengshengqun@163.com</email> (S.-Q.D.); <email>xianluebuzixian28@163.com</email> (X.Y.); <email>smuweiyong@163.com</email> (Y.W.); <email>jiating723@i.smu.edu.cn</email> (J.-T.C.)</aff><aff id="af2-vaccines-08-00063"><label>2</label>Department of Epidemiology and Biostatistics, School of Public Health, Guangdong Medical University, Dongguan 523808, China; <email>wangxj1664@gdmu.edu.cn</email></aff><author-notes><corresp id="c1-vaccines-08-00063"><label>*</label>Correspondence: <email>floriapeng@hotmail.com</email>; Tel.: +86-20-61648526</corresp><fn id="fn1-vaccines-08-00063"><label>&#8224;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>02</day><month>2</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2020</year></pub-date><volume>8</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">355983</issue-id><elocation-id>63</elocation-id><history><date date-type="received"><day>31</day><month>12</month><year>2019</year></date><date date-type="accepted"><day>31</day><month>1</month><year>2020</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>02</month><year>2020</year></date></event><event event-type="pmc-live"><date><day>21</day><month>04</month><year>2020</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-21 13:25:15.073"><day>21</day><month>07</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="vaccines-08-00063.pdf"/><abstract><p>Dengue virus (DENV) has become a global health threat with about half of the world&#8217;s population at risk of infection. Although the disease caused by DENV is self-limiting in the first infection, the antibody-dependent enhancement (ADE) effect increases the mortality in the second infection with a heterotypic virus. Since there is no specific efficient medicine in treatment, it is urgent to develop vaccines to prevent infection and disease progression. Currently, only a live attenuated vaccine, chimeric yellow fever 17D&#8212;tetravalent dengue vaccine (CYD-TDV), has been licensed for clinical use in some countries, and many candidate vaccines are still under research and development. This review discusses the progress, strengths, and weaknesses of the five types of vaccines including live attenuated vaccine, inactivated virus vaccine, recombinant subunit vaccine, viral vectored vaccine, and DNA vaccine.</p></abstract><kwd-group><kwd>dengue virus</kwd><kwd>dengue fever</kwd><kwd>vaccine</kwd><kwd>vector-borne disease</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-08-00063"><title>1. Introduction</title><p>Dengue virus (DENV) is a positive-sense, single-stranded RNA (+ssRNA) virus belonging to genus Flavivirus of family Flaviviridae [<xref rid="B1-vaccines-08-00063" ref-type="bibr">1</xref>]. The mature particles of DENV are spherical and 50 nm in diameter [<xref rid="B2-vaccines-08-00063" ref-type="bibr">2</xref>]. The virus contains multiple copies of three structural proteins, including Envelope (E) protein, Membrane (M) protein, and Capsid (C) protein; a host-derived lipid bilayer envelope; and a single copy of RNA genome [<xref rid="B2-vaccines-08-00063" ref-type="bibr">2</xref>]. DENV has four serotypes (DENV 1&#8211;4) that are transmitted in humans by <italic toggle="yes">Aedes</italic> mosquitoes [<xref rid="B1-vaccines-08-00063" ref-type="bibr">1</xref>]. The most common clinical manifestations are sudden fever with headache, recurrent eyelid pain, generalized muscle pain and joint pain, blushing, anorexia, and abdominal pain. All four serotypes can cause dengue fever (DF), dengue hemorrhagic fever (DHF), and dengue shock syndrome (DSS) [<xref rid="B3-vaccines-08-00063" ref-type="bibr">3</xref>]. DHF and DSS are the more severe effects and more commonly seen in the infection of children and adolescents under fifteen years old [<xref rid="B4-vaccines-08-00063" ref-type="bibr">4</xref>]. DENV infection produces a high titer of neutralizing antibodies, which are considered an important component of the protective immune response [<xref rid="B5-vaccines-08-00063" ref-type="bibr">5</xref>,<xref rid="B6-vaccines-08-00063" ref-type="bibr">6</xref>]. Homotypic protection (protection against the same serotype infection) is considered long-term effective after a serotype infection, while heterotypic protection (cross protection against the other serotypes infection) can last for approximately two years [<xref rid="B7-vaccines-08-00063" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-08-00063" ref-type="bibr">8</xref>]. With the reduction of cross-antibody titer, the second heterotypic dengue infection will be more serious than the first [<xref rid="B9-vaccines-08-00063" ref-type="bibr">9</xref>]. Furthermore, non-neutralizing antibodies can form complexes with DENV particles and can facilitate virus infection to phagocytic cells via Fc receptors, resulting in enhanced infection and leading to DHF and DSS. This phenomenon is called antibody-dependent enhancement (ADE) [<xref rid="B3-vaccines-08-00063" ref-type="bibr">3</xref>]. It is estimated that 390 million dengue infections happen every year, of which 96 million manifest clinically at any level of disease severity [<xref rid="B10-vaccines-08-00063" ref-type="bibr">10</xref>]. There is currently no specific medicine for dengue treatments, and prevention majorly relies on vector control. Therefore, dengue vaccine development is urgently required for dengue prevention.</p><p>Five types of dengue vaccines have been under investigation, including live attenuated vaccine, inactivated vaccine, recombinant subunit vaccine, viral vectored vaccine, and DNA vaccine [<xref rid="B11-vaccines-08-00063" ref-type="bibr">11</xref>]. They act primarily by increasing the immune responses against dengue virus (DENV) E protein and non-structural protein 1 (NS1) [<xref rid="B12-vaccines-08-00063" ref-type="bibr">12</xref>]. Careful studies of the immune responses to DENV help to form an effective strategy for dengue vaccine development [<xref rid="B13-vaccines-08-00063" ref-type="bibr">13</xref>].</p><p>Two major challenges in dengue vaccine development have been discussed. Firstly, although DENV antibodies show protective effects against homotypic or heterotypic DENV infection, the ADE effect resulting from a second heterotypic infection majorly accounts for DHF and DSS [<xref rid="B14-vaccines-08-00063" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-08-00063" ref-type="bibr">15</xref>,<xref rid="B16-vaccines-08-00063" ref-type="bibr">16</xref>]. However, the immune response and pathogenesis of DHF and DSS are not fully understood, which hinders DENV vaccine development [<xref rid="B17-vaccines-08-00063" ref-type="bibr">17</xref>]. Secondly, in vaccine development, we lack a conveniently accessible, cheap, and sensitive animal model capable of simulating the immune responses in humans after infection. Since mice are naturally resistant to DENV infection, human cell chimeric mice and immunodeficient mice sensitive to DENV infection are established to be used as animal models [<xref rid="B18-vaccines-08-00063" ref-type="bibr">18</xref>]. Nonhuman primates (NHPs) are highly potential animal models because they produce a similar immune response to DENV infection as humans, but they are usually used following mouse tests because of the costliness [<xref rid="B19-vaccines-08-00063" ref-type="bibr">19</xref>].</p></sec><sec id="sec2-vaccines-08-00063"><title>2. Live Attenuated Vaccine</title><p>Live attenuated vaccines are antigenic substances composed of a living pathogen, but the pathogen is altered to be less virulent or avirulent [<xref rid="B20-vaccines-08-00063" ref-type="bibr">20</xref>]. Live attenuated vaccines show the advantages of delivering a set of protective antigens and of providing long-term immune protectivity [<xref rid="B20-vaccines-08-00063" ref-type="bibr">20</xref>]. Several live dengue attenuated vaccines have been made with recombinant DNA technology, such as the chimeric yellow fever 17D virus-tetravalent dengue vaccine (CYD-TDV), the recombinant DENV-4 mutant bearing a 30-nucleotide deletion vaccine (rDEN4&#8710;30), and the tetra-live attenuated virus dengue vaccine (DENVax) [<xref rid="B21-vaccines-08-00063" ref-type="bibr">21</xref>].</p><sec id="sec2dot1-vaccines-08-00063"><title>2.1. Live Attenuated Chimeric Yellow Fever&#8211;Dengue Vaccines</title><p>The clinically developed dengue vaccine, CYD-TDV (Dengvaxia<sup>&#174;</sup>) (Sanofi, Paris, France), complying with the International Guidelines for New Vaccines [<xref rid="B22-vaccines-08-00063" ref-type="bibr">22</xref>] has been licensed by several dengue-endemic countries in Asia and Latin America for use in people over 9 years old [<xref rid="B23-vaccines-08-00063" ref-type="bibr">23</xref>]. This vaccine was constructed by replacing the prM/E RNAs of the YF17D (yellow fever virus vaccine strain) with the corresponding sequences of the four dengue serotypes [<xref rid="B24-vaccines-08-00063" ref-type="bibr">24</xref>]. It has been observed in clinical trials that vaccination with CYD-TDV is more effective among people over 9 years old [<xref rid="B25-vaccines-08-00063" ref-type="bibr">25</xref>]. The vaccine-stimulated immunity lasts up to 4 years, and the virus serotype, age, and dengue sera status of the individual before vaccination seem to affect the vaccine effectiveness [<xref rid="B23-vaccines-08-00063" ref-type="bibr">23</xref>]. However, long-term safety assessments showed that the risk of hospitalization for vaccinees was greater than that of placebo controls 3 years after vaccination [<xref rid="B26-vaccines-08-00063" ref-type="bibr">26</xref>]. The reason for the reduced protectivity of CYD-TDV in seronegative subjects and the increased risk of hospitalization for children under 9 years old is unclear [<xref rid="B27-vaccines-08-00063" ref-type="bibr">27</xref>]. The CYD-TDV IIb clinical trial in Thailand and phase III clinical trials in Asia and Latin America found that it was ineffective against DENV2 and that the first-time immunization was less effective than re-immunization [<xref rid="B25-vaccines-08-00063" ref-type="bibr">25</xref>,<xref rid="B28-vaccines-08-00063" ref-type="bibr">28</xref>,<xref rid="B29-vaccines-08-00063" ref-type="bibr">29</xref>]. The better efficacy of re-immunization may be due to the enhanced protectivity in the subjects by stimulating preexisting immune memory [<xref rid="B30-vaccines-08-00063" ref-type="bibr">30</xref>]. In April 2018, the WHO Strategic Advisory Panel recommended that, in CYD-TDV vaccination, the priority assessment of DENV serostatus should be considered to ensure that only dengue-seropositive individuals are vaccinated because CYD-TDV vaccination in seronegative subjects increases the risk of severe dengue [<xref rid="B31-vaccines-08-00063" ref-type="bibr">31</xref>]. Therefore, rapid diagnostic tests are needed before the vaccination. Since DENV belongs to the genus Flavivirus which also includes Zika virus, yellow fever virus, and tick-borne encephalitis virus with highly homologous genomes, proteins, and antibodies, antibody detection for these virus infections has high cross-reactivity and poor reliability [<xref rid="B32-vaccines-08-00063" ref-type="bibr">32</xref>]. The plaque reduction neutralization test (PRNT) is the gold standard for establishing serum status but requires specific laboratory and technical capabilities. Furthermore, the detection process of dengue IgG ELISA is complicated, and the diagnosis of IgG-containing point-of-care tests lack sensitivity and specificity. Therefore, platform evaluation and well-characterized vaccine samples are required to accelerate the clinical trials and market entry for CYD-TDV [<xref rid="B33-vaccines-08-00063" ref-type="bibr">33</xref>].</p></sec><sec id="sec2dot2-vaccines-08-00063"><title>2.2. Live Attenuated rDEN&#8710;30 Vaccines</title><p>There have been some studies to integrate DENV monovalent vaccines with the live attenuated tetravalent vaccine (LATV) [<xref rid="B34-vaccines-08-00063" ref-type="bibr">34</xref>]. However, it is a challenge to develop a LATV that not only has immunogenicity for all four dengue serotypes but also has sufficient attenuation of each monovalent component [<xref rid="B35-vaccines-08-00063" ref-type="bibr">35</xref>,<xref rid="B36-vaccines-08-00063" ref-type="bibr">36</xref>,<xref rid="B37-vaccines-08-00063" ref-type="bibr">37</xref>]. The 3&#8242;- UTR region of the flavivirus genome was chosen as a target for mutagenesis because it plays an important role in viral RNA replication [<xref rid="B38-vaccines-08-00063" ref-type="bibr">38</xref>]. The LATV rDEN4&#8710;30 vaccination stimulated a seven-fold or greater increase in serum neutralizing antibody titer (mean titer = 1:580) on day 28 post-vaccination, and was found to be very tolerant to all of the vaccinees, in which only a mild, asymptomatic macular rash developed, and a transient elevation in the serum level of alanine aminotransferase was noted in several volunteers [<xref rid="B39-vaccines-08-00063" ref-type="bibr">39</xref>]. Prior to this, the experiments testing the ability of the vaccine virus spreading from vaccinees to mosquito vectors showed that no vaccine virus was found in all 352 experimental mosquitoes [<xref rid="B40-vaccines-08-00063" ref-type="bibr">40</xref>]. Moreover, in order to increase the decay rate of rDEN4&#8710;30 and to reduce the side effects, many studies have optimized the paired charge&#8211;mutation of alanine and obtained rDEN-4&#8710;30NS5-K200A and rDEN-4&#8710;30NS5-H201A, which show good compatibility in human vaccination [<xref rid="B41-vaccines-08-00063" ref-type="bibr">41</xref>,<xref rid="B42-vaccines-08-00063" ref-type="bibr">42</xref>,<xref rid="B43-vaccines-08-00063" ref-type="bibr">43</xref>]. Researchers also constructed rDEN4&#8710;30 through chemical mutagenesis and successfully obtained rDEN-4&#8710;30 NS3-S158R [<xref rid="B41-vaccines-08-00063" ref-type="bibr">41</xref>,<xref rid="B44-vaccines-08-00063" ref-type="bibr">44</xref>].</p><p>TV003 is a mixture of four attenuated recombinant dengue vaccine candidates including rDEN1D30, rDEN2/4D30, rDEN3D30/31, and rDEN4D30, which is in the clinical trial phase and has more resistance against DENV2 than CYD-TDV does [<xref rid="B45-vaccines-08-00063" ref-type="bibr">45</xref>,<xref rid="B46-vaccines-08-00063" ref-type="bibr">46</xref>]. It was found that, after vaccinated with TV003, antibodies of the four DENV serotypes were detected in 91.7% of subjects and that the protective potency against DENV2 was superior to that of CYD-TDV vaccination, with the only adverse reaction presenting a mild rash [<xref rid="B47-vaccines-08-00063" ref-type="bibr">47</xref>]. More DENV2 attenuated virus components were added to TV005 than to TV003. A phase I clinical trial showed that a single vaccination of TV005 caused a relatively balanced immune response in 90% of vaccinnees while TV003 vaccination only caused immune response in 76% of recipients [<xref rid="B46-vaccines-08-00063" ref-type="bibr">46</xref>]. TV003 and TV005 induce the most balanced neutralizing antibodies among the five LATVs (TV001&#8211;TV005) [<xref rid="B27-vaccines-08-00063" ref-type="bibr">27</xref>].</p><p>TV003/TV005 is very different from CYD-TDV in characteristics due to their different virus particle structure, infectivity, and immunogenicity. For example, CYD results in a higher risk of viremia, lower resistance against DENV2 virus, and lower level of induced immune balance than TV003/TV005 [<xref rid="B27-vaccines-08-00063" ref-type="bibr">27</xref>].</p></sec><sec id="sec2dot3-vaccines-08-00063"><title>2.3. Live Attenuated Chimeric Tetra-Dengue Vaccines</title><p>Scientists used the attenuated virus DENV2 PDK-53 as a genetic backbone to replace its coding sequences with that of DENV1, DENV3, and DENV4; the recombinant RNAs were used to transfect Vero cells to produce a vaccine candidate called DENVax [<xref rid="B48-vaccines-08-00063" ref-type="bibr">48</xref>]. These tetra-live attenuated virus (TLAV) vaccines are undergoing clinical trials [<xref rid="B44-vaccines-08-00063" ref-type="bibr">44</xref>]. To investigate whether the vaccination of DENVax in mothers would affect the re-inoculation effects in offspring, AG129 mice were used as the model, and it was found that the vaccination effects of the pups born by PDK53 immunized mothers may be interfered with by their maternal antibodies [<xref rid="B23-vaccines-08-00063" ref-type="bibr">23</xref>].</p><p>In summary, the live attenuated vaccine CYD-TDV has a definitive protectivity in DENV seropositive subjects over 9 years old. The rDEN&#8710;30 vaccine makes up for the low immune balance of CYD-TDV. DENVax is highly immunogenic tolerant and is hard to induce systemic reactions.</p></sec></sec><sec id="sec3-vaccines-08-00063"><title>3. Inactivated Virus Vaccines</title><p>Inactivated vaccines are antigenic substances composed of inactivated material from a pathogen (such as virus or bacterium) which can elicit protectivity against the live pathogen [<xref rid="B49-vaccines-08-00063" ref-type="bibr">49</xref>]. A DENV2 inactivated vaccine named <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="S16803">S16803</ext-link> was developed by formalin inactivation and sucrose centrifugal purification and demonstrated its effectiveness in rhesus monkeys [<xref rid="B49-vaccines-08-00063" ref-type="bibr">49</xref>,<xref rid="B50-vaccines-08-00063" ref-type="bibr">50</xref>]. The immunogenicity of the recombinant subunit protein vaccine (R80E) and live attenuated vaccine (DENV2 PDK-50) was compared with the inactivated vaccine <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="S16803">S16803</ext-link> in rhesus monkeys, and it was found that only DENV2 PDK-50 can produce stable titers of antibodies [<xref rid="B51-vaccines-08-00063" ref-type="bibr">51</xref>]. Tetravalent purified formalin-inactivated virus (TPIV) is an inactivated vaccine containing four inactivated dengue serotypes [<xref rid="B52-vaccines-08-00063" ref-type="bibr">52</xref>]. Rhesus monkey vaccination initiated with TPIV or tetravalent DNA vaccine (TDNA) and then enhanced with TLAV showed promoted humoral immunity against dengue virus compared with the vaccination using only one type of vaccine [<xref rid="B53-vaccines-08-00063" ref-type="bibr">53</xref>]. It is reported that the antibody titers of four serotypes of DENV reached a certain height by using TPIV to initiate immunization and then TLAV to enhance immunization [<xref rid="B52-vaccines-08-00063" ref-type="bibr">52</xref>].</p><p>Inactivated dengue virus vaccine uses C, M, E, and NS1 protein components as antigens to stimulate immunity, but composite vaccines arouse better protectivity than single-type vaccines. Compared with live attenuated vaccines, inactivated virus vaccines are safer with no hidden danger of reactivation and better controlled immune balance.</p></sec><sec id="sec4-vaccines-08-00063"><title>4. Recombinant Subunit Vaccines</title><p>Recombinant subunit vaccines are antigenic proteins expressed by prokaryotic or eukaryotic cells to stimulate long-lasting protective/therapeutic immune responses [<xref rid="B54-vaccines-08-00063" ref-type="bibr">54</xref>,<xref rid="B55-vaccines-08-00063" ref-type="bibr">55</xref>,<xref rid="B56-vaccines-08-00063" ref-type="bibr">56</xref>]. Expression of the recombinant dengue proteins in <italic toggle="yes">E. coli</italic> is relatively easy, but meanwhile, there are some problems of endotoxin contamination and improper protein folding [<xref rid="B57-vaccines-08-00063" ref-type="bibr">57</xref>]. The recombinant envelope protein domain III (EDIII) expressed by <italic toggle="yes">E. coli</italic> and purified by metal affinity membrane chromatography was shown to successfully induce antibodies against the four serotypes of dengue in mice [<xref rid="B58-vaccines-08-00063" ref-type="bibr">58</xref>], and these antibodies also protected lactating mice from infection [<xref rid="B59-vaccines-08-00063" ref-type="bibr">59</xref>]. Another tetravalent recombinant subunit vaccine combined with alum adjuvant in vaccination produces high titers of antibodies in mice, but it induced only DENV2 antibodies in adult macaques [<xref rid="B60-vaccines-08-00063" ref-type="bibr">60</xref>,<xref rid="B61-vaccines-08-00063" ref-type="bibr">61</xref>]. Recombinant dengue proteins fused with a lipoprotein were expressed in a lipid form, thereby eliminating the use of adjuvants, and the viral antigens successfully provoked immune responses against the four serotypes in mice [<xref rid="B60-vaccines-08-00063" ref-type="bibr">60</xref>,<xref rid="B62-vaccines-08-00063" ref-type="bibr">62</xref>,<xref rid="B63-vaccines-08-00063" ref-type="bibr">63</xref>]. In addition, EDIII-P64K was an adjuvant-containing tetravalent dengue vaccine expressing P64K of <italic toggle="yes">Neisseria meningitidis</italic> and EDIII of different DENV serotypes [<xref rid="B64-vaccines-08-00063" ref-type="bibr">64</xref>]. The mice were immunized with EDIII-P64K three times, and high titers of antibodies against DENV1&#8211;3 and low titers of antibodies against DENV4 were produced [<xref rid="B65-vaccines-08-00063" ref-type="bibr">65</xref>]. Furthermore, a combination of DENV1&#8211;2 EDIII and DENV3&#8211;4 EDIII linked with a Gly-Ser linker was expressed in <italic toggle="yes">E. coli</italic>, and this vaccine successfully induced immune protection against the four serotypes of DENV in mice. [<xref rid="B66-vaccines-08-00063" ref-type="bibr">66</xref>]. LTB-scEDIII was a fusion protein expressed by <italic toggle="yes">Saccharomyces cerevisiae,</italic> containing the <italic toggle="yes">E. coli</italic> heat-labile toxin protein B-subunit (LTB) and the synthetic consensus dengue envelope domain III (scEDIII) from the four serotypes. Oral immunization with the intact recombinant yeast cells (rYC) and the cell-free extracts (CFE) was found to stimulate systemic humoral and mucosal immune responses in mice. The titers of neutralizing antibodies in CFE-fed mice were higher than that in rYC-fed mice [<xref rid="B67-vaccines-08-00063" ref-type="bibr">67</xref>]. </p><p>The most promising subunit vaccine is V180, which consists of a truncated protein DEN-80E expressed in insect cells. V180 vaccination in a low dose successfully induced a high level of immune protection against DENV in mice and rhesus monkeys [<xref rid="B68-vaccines-08-00063" ref-type="bibr">68</xref>]. It has been reported that V180-immunized rhesus monkeys can be protected from viremia [<xref rid="B69-vaccines-08-00063" ref-type="bibr">69</xref>]. Sf-9 cells expressing DENV E protein elicited not only specific Th2 responses and weak Th1 responses but also neutralizing antibodies against DENV1-4 [<xref rid="B70-vaccines-08-00063" ref-type="bibr">70</xref>,<xref rid="B71-vaccines-08-00063" ref-type="bibr">71</xref>]. Furthermore, recombinant DENV2 NS1 protein expressed with S-2 cells successfully elicited immune protection in mice [<xref rid="B12-vaccines-08-00063" ref-type="bibr">12</xref>]. A fusion protein containing the DENV consensus domain III (cEDIII) and polymeric immunoglobulin G scaffold (PIGS) was expressed in Chinese ovary hamster cells and transgenic plants, which induced high titer of IgG antibody in mice and showed neutralizing potential against DENV2 [<xref rid="B72-vaccines-08-00063" ref-type="bibr">72</xref>]. The production of DENV EDIII in transgenic non-nicotine tobacco illustrates the feasibility of plant transgenic vaccine [<xref rid="B73-vaccines-08-00063" ref-type="bibr">73</xref>], but it had not been tested in any animal models. A single polypeptide chain comprising EDIII of all four serotypes tetra-EDIII (tEDIII) and coenzyme 1 (Co1) was expressed in rice, and the transgenic rice containing 100 &#956;g of tEDIIII-Co1 was fed to mice, presenting strong antigen-specific B and T cell responses [<xref rid="B74-vaccines-08-00063" ref-type="bibr">74</xref>]. </p><p>Compared with live attenuated vaccines, recombinant subunit vaccines are more likely to trigger balanced immune responses against the four serotypes, reducing the incidence of ADE effect [<xref rid="B55-vaccines-08-00063" ref-type="bibr">55</xref>,<xref rid="B56-vaccines-08-00063" ref-type="bibr">56</xref>].</p></sec><sec id="sec5-vaccines-08-00063"><title>5. Viral Vectored Vaccines</title><p>Vaccinia virus, adenovirus, and alphavirus vectors have been used as delivery vectors for DENV antigens in vaccine development [<xref rid="B11-vaccines-08-00063" ref-type="bibr">11</xref>]. It is recorded that prM, E, NS1, and NS2A proteins of DENV4 expressed low efficiency in Cidofovir-resistant vaccinia (WR) strain [<xref rid="B75-vaccines-08-00063" ref-type="bibr">75</xref>]. Full-length or c-terminal truncated vaccinia virus were recombinated to express DENV E protein to enhance their protectivity [<xref rid="B76-vaccines-08-00063" ref-type="bibr">76</xref>]. However, the non-attenuated WR strain may bring safety hazards. Immunization of mice with these recombinant vaccines induced only a low level of specific antibodies against E protein [<xref rid="B77-vaccines-08-00063" ref-type="bibr">77</xref>,<xref rid="B78-vaccines-08-00063" ref-type="bibr">78</xref>]. Based on the safer modified vaccinia Ankara (MVA) virus, MVA-DENV2&#8211;80%E and MVA-DENV4&#8211;80%E were then constructed, which can induce high anti-E antibodies in mice, but the former produced low levels of antibodies against DENV2 in rhesus monkeys [<xref rid="B79-vaccines-08-00063" ref-type="bibr">79</xref>].</p><p>Adenoviral vectors show many advantages such as easy gene manipulation, easy detection of gene replication defects, and high level of protein expression [<xref rid="B80-vaccines-08-00063" ref-type="bibr">80</xref>]. A recombinant replication-defective adenovirus (rAd) expressing the E protein of DENV2 was constructed to vaccinate the mice intraperitoneally, which successfully stimulated DENV2 antibodies and specific T cell immunity in these mice [<xref rid="B81-vaccines-08-00063" ref-type="bibr">81</xref>,<xref rid="B82-vaccines-08-00063" ref-type="bibr">82</xref>]. Furthermore, when first immunized with rAd and then boosted with a DNA vaccine expressing EDIII, the mice presented protectivity against DENV2 and DENV4 [<xref rid="B83-vaccines-08-00063" ref-type="bibr">83</xref>]. The cAdVaxD (1&#8211;2) and cAdVaxD (3&#8211;4), two divalent complex Adenovirus (cAd) -vectored vaccines expressing prM and E of the DENVs, could induce antibodies against four serotypes and T cell immune protection in rhesus monkeys [<xref rid="B84-vaccines-08-00063" ref-type="bibr">84</xref>,<xref rid="B85-vaccines-08-00063" ref-type="bibr">85</xref>].</p><p>In addition, the alphavirus-vectored dengue vaccines have high potential. High levels of antigen expression were detected in a single round of vaccination with Venezuelan equine encephalitis virus replicon particles (VRP), and antigen presentation was guaranteed due to the adjuvant activity of VRP and the effect of VRP on dendritic cells (DC) in lymph nodes [<xref rid="B86-vaccines-08-00063" ref-type="bibr">86</xref>,<xref rid="B87-vaccines-08-00063" ref-type="bibr">87</xref>]. VRP expressing the M and E proteins of DENV1 induced protective antibodies in cynomolgus monkeys [<xref rid="B88-vaccines-08-00063" ref-type="bibr">88</xref>]. Immunization with DENV2 VRP in mice produced specific IgG and neutralizing antibodies against DENV2. VRP was constructed to express prM-E and E85; both E85-VRP and prM-E-VRP produced a serotype-specific antibody against EDIII in rhesus monkeys immunization, but E85-VRP developed antibodies faster and with higher titers [<xref rid="B89-vaccines-08-00063" ref-type="bibr">89</xref>]. The tetravalent E85-VRP dengue vaccine induced a balanced immune response and protectivity against DENV1&#8211;4 in monkeys with 2 doses given 6 weeks apart [<xref rid="B89-vaccines-08-00063" ref-type="bibr">89</xref>]. A tetravalent VRP vaccine induced antibodies at an equivalent level as a monovalent vaccine did after a single immunization, indicating that it could overcome serotype interference [<xref rid="B90-vaccines-08-00063" ref-type="bibr">90</xref>]. Although the magnitude of the neonatal immune response was lower than that of adult mice, experiments have shown that the VRP vaccine produced a strong protective immunity after a single neonatal immunization [<xref rid="B90-vaccines-08-00063" ref-type="bibr">90</xref>].</p><p>Viral vectored vaccine is still the best way to induce cellular immunity, and it is hopeful to induce stronger humoral responses. Compared with the other viral vectored vaccines, adenoviral vectors are superior in easy genetic manipulation, detection of gene replication defects, and high antigen expression.</p></sec><sec id="sec6-vaccines-08-00063"><title>6. DNA Vaccines</title><p>A DNA vaccine is a plasmid containing one or more genes encoding specific antigens, which can be injected in vivo to express antigens and to stimulate immune responses [<xref rid="B91-vaccines-08-00063" ref-type="bibr">91</xref>]. A DNA vaccine expressing prM and 92% of E protein of DENV2 was used to vaccinate BALB/c mice intradermally, and anti-dengue antibodies were detected in all these mice [<xref rid="B91-vaccines-08-00063" ref-type="bibr">91</xref>]. When the DNA vaccine expressing E80 (80% of E protein) was compared with the one expressing ME100 (prM and 100% of E protein), the ME100 was found to stimulate antibody production more efficiently in mice [<xref rid="B92-vaccines-08-00063" ref-type="bibr">92</xref>]. <italic toggle="yes">Aotus nancymae</italic> monkeys were immunized with D1ME100 intradermally and intramuscularly and then boosted at 1 and 5 months post priming; <italic toggle="yes">Aotus</italic> monkeys were partially or completely protected against DENV1 challenge at 6 months post priming [<xref rid="B93-vaccines-08-00063" ref-type="bibr">93</xref>]. In a human test, D1ME100 showed safe and well-tolerant effects in the first phase of vaccination and the most common side effect was mild pain or tenderness at the injection site. However, the immunogenicity of the vaccine was poor; only 41.6% of the subjects receiving high-dose vaccination produced neutralizing antibodies, and no neutralizing antibody response was detected in the low-dose group [<xref rid="B94-vaccines-08-00063" ref-type="bibr">94</xref>].</p><p>A DNA vaccine expressing DENV2 prM/E fused with the immunostimulatory CpG motif was reported to produce protective immunity against DENV2 and to improve the neutralizing antibody response efficiently compared with the DENV2 prM/E DNA vaccine [<xref rid="B95-vaccines-08-00063" ref-type="bibr">95</xref>]. Moreover, the DENV2 DNA vaccine expressing a recombinant protein containing DENV2 EDIII and <italic toggle="yes">Escherichia</italic> maltose-binding protein (MBP) was used to immunize mice and was found to be able to elicit neutralizing antibodies in mice [<xref rid="B96-vaccines-08-00063" ref-type="bibr">96</xref>]. Scientists have evaluated the efficacy of three nonreplicating DENV2 vaccines in rhesus monkeys alone or in combination: DENV2 prM/E DNA vaccine (D), DENV2 EDIII and MBP recombinant fusion protein (R), and purified inactivated virus particles (P). The results showed that DNA vaccine used alone induced a moderate level of neutralizing antibodies while DNA vaccine combined with recombinant proteins induced higher titers of antibodies and neutralization levels. The antibody titers of DR/DR/DR, DP/DP/DP, and R/R/R vaccination were the highest, while the titer of D/D/D vaccination was the lowest. Interestingly, significant immune protection against viremia was observed only in the animals vaccinated with P [<xref rid="B97-vaccines-08-00063" ref-type="bibr">97</xref>]. </p><p>Some guiding proteins targeting the immune system were used to enhance the protectivity in DNA vaccine development. For example, integrating antigen sequence into lysosomal membrane protein increases the expression of MHC class II antigens, thereby enhancing the production of CD4 T cells and anti-CD4 antigens and ultimately improving the immunogenicity of the DENV2 prM/E DNA vaccine [<xref rid="B98-vaccines-08-00063" ref-type="bibr">98</xref>]. A DNA vaccine expressing an antigen fused with a single-chain Fv antibody (scFv) specific for the DC endocytic receptor DEC205 could induce a strong immune response to the target antigen [<xref rid="B99-vaccines-08-00063" ref-type="bibr">99</xref>]. </p><p>The combination of tetravalent DNA vaccine (TVDV), tetravalent purified formalin-inactivated virus (TPIV), and tetra-live attenuated virus (TLAV)-enhanced vaccination strategy was tested in rhesus monkeys, and monkeys immunized with TVDV/TVDV/TLAV were partially protected while TPIV/TLAV immunized monkeys were completely free of viremia [<xref rid="B64-vaccines-08-00063" ref-type="bibr">64</xref>]. In phase 1 clinical trials, a TVDV with Vaxfectin<sup>&#174;</sup> (Vical, Boulder, CO, USA) adjuvant was found to trigger anti-dengue T cell IFN&#947; response with ideal safety [<xref rid="B100-vaccines-08-00063" ref-type="bibr">100</xref>]. </p><p>DNA vaccines are stable, easy to prepare, low in cost, and suitable for mass production but lack high immunogenicity. Therefore, plasmid modification with highly efficient promoters, alternative delivery strategies, multiple doses, and co-immunization with adjuvants may be the ways to solve this problem [<xref rid="B101-vaccines-08-00063" ref-type="bibr">101</xref>].</p></sec><sec sec-type="conclusions" id="sec7-vaccines-08-00063"><title>7. Conclusions and Future Perspectives</title><p>In general, there are five types of vaccines against DENV including live attenuated vaccine, inactivated vaccine, recombinant subunit vaccine, viral vectored vaccine, and DNA vaccine. Among the dengue vaccine candidates in use or in clinical trials (<xref rid="vaccines-08-00063-t001" ref-type="table">Table 1</xref>), live attenuated tetravalent dengue vaccine (CYD-TDV) can stimulate neutralizing antibodies in humans, but the lack of ability to neutralize DENV2 virus limits its use. Immunization of female mice with the live attenuated vaccine DENVax may interfere with the vaccination effect of the born pups. Compared with the live attenuated vaccines, recombinant subunit vaccines are more likely to trigger a balanced immune response against the four serotypes but bring problems of endotoxin contamination and improper protein folding. Adenoviral vectored vaccines show many advantages, such as ease of genetic manipulation, easy detection of gene replication defects, and high levels of protein expression. Alphavirus-vectored dengue vaccines produce a strong protective immunity after a single neonatal immunization in mice. DNA vaccines are stable, low in cost, and easy for mass production; however, the problem of low immunogenicity remains to be solved. In terms of vaccination strategy, the immunization priming and boosting with different vaccine combinations has been used to develop successful protectivity in animals. Furthermore, new vaccine development concepts have been proved to be viable, such as DENV NS1-based and mosquito-based immunization strategies [<xref rid="B12-vaccines-08-00063" ref-type="bibr">12</xref>]. In addition, studying the immune mechanism of viral components in disease transmission is helpful to break through the bottleneck of vaccine development.</p></sec></body><back><notes><title>Author Contributions</title><p>Conceptualization, S.-Q.D.; methodology, S.-Q.D. and X.Y.; data proof, S.-Q.D., X.Y., Y.W., X.-J.W., and J.-T.C.; writing&#8212;original draft preparation, S.-Q.D. and X.Y.; writing&#8212;review and editing, S.-Q.D. and H.-J.P.; funding acquisition, H.-J.P. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This research was funded by National Natural Science Foundation of China (81572012, 81772217, 20180907, and 81971954), by Guangdong Provincial Natural Science Foundation Project (2016A030311025 and 2017A030313694), by Science and Technology Planning Project of Guangdong Province (2018A050506038), and by Key project of Guangzhou science research (201904020011) to H.J.P.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-08-00063"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clyde</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kyle</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>E.</given-names></name></person-group><article-title>Recent Advances in Deciphering Viral and Host Determinants of Dengue Virus Replication and Pathogenesis</article-title><source>J. Virol.</source><year>2006</year><volume>80</volume><fpage>11418</fpage><lpage>11431</lpage><pub-id pub-id-type="doi">10.1128/JVI.01257-06</pub-id><pub-id pub-id-type="pmid">16928749</pub-id><pub-id pub-id-type="pmcid">PMC1642597</pub-id></element-citation></ref><ref id="B2-vaccines-08-00063"><label>2.</label><element-citation publication-type="book"><source>Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control: New Edition</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2009</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK143157/">https://www.ncbi.nlm.nih.gov/books/NBK143157/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-09-24">(accessed on 24 September 2019)</date-in-citation><pub-id pub-id-type="pmid">23762963</pub-id></element-citation></ref><ref id="B3-vaccines-08-00063"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murrell</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Butler</surname><given-names>M.</given-names></name></person-group><article-title>Review of dengue virus and the development of a vaccine</article-title><source>Biotechnol. Adv.</source><year>2011</year><volume>29</volume><fpage>239</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2010.11.008</pub-id><pub-id pub-id-type="pmid">21146601</pub-id></element-citation></ref><ref id="B4-vaccines-08-00063"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hammon</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Rundnick</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sather</surname><given-names>G.E.</given-names></name></person-group><article-title>Viruses Associated with Epidemic Hemorrhagic Fevers of the Philippines and Thailand</article-title><source>Science</source><year>1960</year><volume>131</volume><fpage>1102</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1126/science.131.3407.1102</pub-id><pub-id pub-id-type="pmid">14399343</pub-id></element-citation></ref><ref id="B5-vaccines-08-00063"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>R.S.L.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Chow</surname><given-names>A.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Ooi</surname><given-names>E.E.</given-names></name></person-group><article-title>Neutralization of dengue virus in the presence of Fc receptor-mediated phagocytosis distinguishes serotype-specific from cross-neutralizing antibodies</article-title><source>Antivir. Res.</source><year>2012</year><volume>96</volume><fpage>340</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2012.09.018</pub-id><pub-id pub-id-type="pmid">23041143</pub-id></element-citation></ref><ref id="B6-vaccines-08-00063"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodrigo</surname><given-names>W.W.S.I.</given-names></name><name name-style="western"><surname>Block</surname><given-names>O.K.T.</given-names></name><name name-style="western"><surname>Lane</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sukupolvi-Petty</surname><given-names>S.</given-names></name><name name-style="western"><surname>Goncalvez</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Schlesinger</surname><given-names>J.J.</given-names></name></person-group><article-title>Dengue virus neutralization is modulated by igg antibody subclass and fc&#947; receptor subtype</article-title><source>Virology</source><year>2009</year><volume>394</volume><fpage>175</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2009.09.024</pub-id><pub-id pub-id-type="pmid">19833371</pub-id><pub-id pub-id-type="pmcid">PMC2783259</pub-id></element-citation></ref><ref id="B7-vaccines-08-00063"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montoya</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gresh</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mercado</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Vargas</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Gutierrez</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kuan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Balmaseda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>E.</given-names></name></person-group><article-title>Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year</article-title><source>PLoS Neglect. Trop. Dis.</source><year>2013</year><volume>7</volume><elocation-id>e2357</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0002357</pub-id><pub-id pub-id-type="pmcid">PMC3738476</pub-id><pub-id pub-id-type="pmid">23951377</pub-id></element-citation></ref><ref id="B8-vaccines-08-00063"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reich</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Shrestha</surname><given-names>S.</given-names></name><name name-style="western"><surname>King</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Rohani</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lessler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kalayanarooj</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>I.K.</given-names></name><name name-style="western"><surname>Gibbons</surname><given-names>R.V.</given-names></name><name name-style="western"><surname>Burke</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>D.A.</given-names></name></person-group><article-title>Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity</article-title><source>J. R. Soc. Interface</source><year>2013</year><volume>10</volume><fpage>20130414</fpage><pub-id pub-id-type="doi">10.1098/rsif.2013.0414</pub-id><pub-id pub-id-type="pmid">23825116</pub-id><pub-id pub-id-type="pmcid">PMC3730691</pub-id></element-citation></ref><ref id="B9-vaccines-08-00063"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Endy</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>I.K.</given-names></name><name name-style="western"><surname>Mammen</surname><given-names>M.P.</given-names></name></person-group><article-title>Prospective Cohort Studies of Dengue Viral Transmission and Severity of Disease</article-title><source>Curr. Top. Microbiol.</source><year>2010</year><volume>338</volume><fpage>1</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-3-642-02215-9_1</pub-id><pub-id pub-id-type="pmid">19802574</pub-id></element-citation></ref><ref id="B10-vaccines-08-00063"><label>10.</label><element-citation publication-type="web"><article-title>Global Strategy for dengue prevention and control, 2012&#8211;2020</article-title><comment>World Health Organization</comment><year>2009</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/denguecontrol/9789241504034/en/">https://www.who.int/denguecontrol/9789241504034/en/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-09-24">(accessed on 24 September 2019)</date-in-citation></element-citation></ref><ref id="B11-vaccines-08-00063"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yauch</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Shresta</surname><given-names>S.</given-names></name></person-group><article-title>Dengue virus vaccine development</article-title><source>Adv. Virus Res.</source><year>2014</year><volume>88</volume><fpage>315</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">24373316</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/B978-0-12-800098-4.00007-6</pub-id></element-citation></ref><ref id="B12-vaccines-08-00063"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>G.</given-names></name></person-group><article-title>Vaccines and immunization strategies for dengue prevention</article-title><source>Emerg. Microbes Infec.</source><year>2016</year><volume>5</volume><fpage>e77</fpage><pub-id pub-id-type="doi">10.1038/emi.2016.74</pub-id><pub-id pub-id-type="pmid">27436365</pub-id><pub-id pub-id-type="pmcid">PMC5141265</pub-id></element-citation></ref><ref id="B13-vaccines-08-00063"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>X.</given-names></name></person-group><article-title>Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine</article-title><source>Cell Mol. Immunol.</source><year>2016</year><volume>13</volume><fpage>36</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1038/cmi.2015.76</pub-id><pub-id pub-id-type="pmid">26435066</pub-id><pub-id pub-id-type="pmcid">PMC4711684</pub-id></element-citation></ref><ref id="B14-vaccines-08-00063"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Modhiran</surname><given-names>N.</given-names></name><name name-style="western"><surname>Watterson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Panetta</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Sester</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hume</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Stacey</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Young</surname><given-names>P.R.</given-names></name></person-group><article-title>Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity</article-title><source>Sci. Transl. Med.</source><year>2015</year><volume>7</volume><fpage>142</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aaa3863</pub-id><pub-id pub-id-type="pmid">26355031</pub-id></element-citation></ref><ref id="B15-vaccines-08-00063"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ritchie</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Pyke</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Sonja</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Andrew</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mores</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Christofferson</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Gubler</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Hurk</surname><given-names>A.F.</given-names></name></person-group><article-title>An explosive epidemic of denv-3 in cairns, australia</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e68137</elocation-id><pub-id pub-id-type="doi">10.1371/annotation/a8dfd4ee-f4b7-443e-bf78-ebb0dab4e55b</pub-id><pub-id pub-id-type="pmid">23874522</pub-id><pub-id pub-id-type="pmcid">PMC3712959</pub-id></element-citation></ref><ref id="B16-vaccines-08-00063"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alvarez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rodriguez-Roche</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bernardo</surname><given-names>L.</given-names></name><name name-style="western"><surname>V&#225;zquez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Morier</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>D.</given-names></name><name name-style="western"><surname>Castro</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kouri</surname><given-names>G.</given-names></name><name name-style="western"><surname>Halstead</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Guzman</surname><given-names>M.G.</given-names></name></person-group><article-title>Dengue hemorrhagic fever caused by sequential dengue 1-3 virus infections over a long time interval: Havana epidemic, 2001&#8211;2002</article-title><source>Am. J. Trop. Med. Hyg.</source><year>2006</year><volume>75</volume><fpage>1113</fpage><lpage>1117</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.2006.75.1113</pub-id><pub-id pub-id-type="pmid">17172378</pub-id></element-citation></ref><ref id="B17-vaccines-08-00063"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halstead</surname><given-names>S.</given-names></name></person-group><article-title>Pathogenesis of dengue: Challenges to molecular biology</article-title><source>Science</source><year>1988</year><volume>239</volume><fpage>476</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1126/science.239.4839.476</pub-id><pub-id pub-id-type="pmid">3277268</pub-id></element-citation></ref><ref id="B18-vaccines-08-00063"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yauch</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Shresta</surname><given-names>S.</given-names></name></person-group><article-title>Mouse models of dengue virus infection and disease</article-title><source>Antiviral Res.</source><year>2008</year><volume>80</volume><fpage>87</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2008.06.010</pub-id><pub-id pub-id-type="pmid">18619493</pub-id><pub-id pub-id-type="pmcid">PMC3048811</pub-id></element-citation></ref><ref id="B19-vaccines-08-00063"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sariol</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>White</surname><given-names>L.J.</given-names></name></person-group><article-title>Utility, Limitations, and Future of Non-Human Primates for Dengue Research and Vaccine Development</article-title><source>Front. Immunol.</source><year>2014</year><volume>5</volume><fpage>452</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2014.00452</pub-id><pub-id pub-id-type="pmid">25309540</pub-id><pub-id pub-id-type="pmcid">PMC4174039</pub-id></element-citation></ref><ref id="B20-vaccines-08-00063"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whitehead</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Blaney</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Durbin</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>B.R.</given-names></name></person-group><article-title>Prospects for a dengue virus vaccine</article-title><source>Nat. Rev. Microbiol.</source><year>2007</year><volume>5</volume><fpage>518</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1038/nrmicro1690</pub-id><pub-id pub-id-type="pmid">17558424</pub-id></element-citation></ref><ref id="B21-vaccines-08-00063"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Butler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.C.</given-names></name></person-group><article-title>Using recombinant DNA technology for the development of live-attenuated dengue vaccines</article-title><source>Enzyme Microb. Technol.</source><year>2012</year><volume>51</volume><fpage>67</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.enzmictec.2012.05.005</pub-id><pub-id pub-id-type="pmid">22664189</pub-id></element-citation></ref><ref id="B22-vaccines-08-00063"><label>22.</label><element-citation publication-type="web"><article-title>WHO expert committee on biological standardization</article-title><comment>World Health Organization</comment><year>2011</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/biologicals/expert_committee/en/">https://www.who.int/biologicals/expert_committee/en/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-09-24">(accessed on 24 September 2019)</date-in-citation></element-citation></ref><ref id="B23-vaccines-08-00063"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guy</surname><given-names>B.</given-names></name><name name-style="western"><surname>Noriega</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ochiai</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>L&#8217;azou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Delore</surname><given-names>V.</given-names></name><name name-style="western"><surname>Skipetrova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Verdier</surname><given-names>F.</given-names></name><name name-style="western"><surname>Coudeville</surname><given-names>L.</given-names></name><name name-style="western"><surname>Savarino</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>N.</given-names></name></person-group><article-title>A recombinant live attenuated tetravalent vaccine for the prevention of dengue</article-title><source>Expert Rev. Vaccines</source><year>2017</year><volume>7</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1080/14760584.2017.1335201</pub-id><pub-id pub-id-type="pmid">28590795</pub-id></element-citation></ref><ref id="B24-vaccines-08-00063"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guy</surname><given-names>B.</given-names></name><name name-style="western"><surname>Guirakhoo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Barban</surname><given-names>V.</given-names></name><name name-style="western"><surname>Higgs</surname><given-names>S.</given-names></name><name name-style="western"><surname>Monath</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>J.</given-names></name></person-group><article-title>Preclinical and clinical development of yfv 17d-based chimeric vaccines against dengue, west nile and japanese encephalitis viruses</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>632</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.09.098</pub-id><pub-id pub-id-type="pmid">19808029</pub-id></element-citation></ref><ref id="B25-vaccines-08-00063"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hadinegoro</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Arredondo-Garc&#237;a</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Capeding</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Deseda</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chotpitayasunondh</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dietze</surname><given-names>R.</given-names></name><name name-style="western"><surname>Muhammad Ismail</surname><given-names>H.I.</given-names></name><name name-style="western"><surname>Reynales</surname><given-names>H.</given-names></name><name name-style="western"><surname>Limkittikul</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rivera-Medina</surname><given-names>D.M.</given-names></name><etal/></person-group><article-title>Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>373</volume><fpage>1195</fpage><lpage>1206</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1506223</pub-id><pub-id pub-id-type="pmid">26214039</pub-id></element-citation></ref><ref id="B26-vaccines-08-00063"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sridhar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Luedtke</surname><given-names>A.</given-names></name><name name-style="western"><surname>Langevin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bonaparte</surname><given-names>M.</given-names></name><name name-style="western"><surname>Machabert</surname><given-names>T.</given-names></name><name name-style="western"><surname>Savarino</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zambrano</surname><given-names>B.</given-names></name><name name-style="western"><surname>Moureau</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khromava</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy</article-title><source>N. Engl. J. Med.</source><year>2018</year><volume>379</volume><fpage>327</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1800820</pub-id><pub-id pub-id-type="pmid">29897841</pub-id></element-citation></ref><ref id="B27-vaccines-08-00063"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Whitehead</surname><given-names>S.S.</given-names></name></person-group><article-title>Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD vaccine?</article-title><source>Expert Rev. Vaccines</source><year>2016</year><volume>15</volume><fpage>509</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1586/14760584.2016.1115727</pub-id><pub-id pub-id-type="pmid">26559731</pub-id><pub-id pub-id-type="pmcid">PMC4956407</pub-id></element-citation></ref><ref id="B28-vaccines-08-00063"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabchareon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sirivichayakul</surname><given-names>C.</given-names></name><name name-style="western"><surname>Limkittikul</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chanthavanich</surname><given-names>P.</given-names></name><name name-style="western"><surname>Suvannadabba</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jiwariyavej</surname><given-names>V.</given-names></name><name name-style="western"><surname>Dulyachai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Pengsaa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wartel</surname><given-names>T.A.</given-names></name><etal/></person-group><article-title>Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled phase 2b trial</article-title><source>Lancet</source><year>2012</year><volume>380</volume><fpage>1559</fpage><lpage>1567</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)61428-7</pub-id><pub-id pub-id-type="pmid">22975340</pub-id></element-citation></ref><ref id="B29-vaccines-08-00063"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Capeding</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Hadinegoro</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Ismail</surname><given-names>H.I.</given-names></name><name name-style="western"><surname>Chotpitayasunondh</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chua</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Luong</surname><given-names>C.Q.</given-names></name><name name-style="western"><surname>Rusmil</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wirawan</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Nallusamy</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomised, observer-masked, placebo-controlled trial</article-title><source>Lancet</source><year>2014</year><volume>384</volume><fpage>1358</fpage><lpage>1365</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(14)61060-6</pub-id><pub-id pub-id-type="pmid">25018116</pub-id></element-citation></ref><ref id="B30-vaccines-08-00063"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dorigatti</surname><given-names>I.</given-names></name><name name-style="western"><surname>Aguas</surname><given-names>R.</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Guy</surname><given-names>B.</given-names></name><name name-style="western"><surname>Coudeville</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Saville</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>N.M.</given-names></name></person-group><article-title>Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>3746</fpage><lpage>3751</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.05.059</pub-id><pub-id pub-id-type="pmid">26051515</pub-id><pub-id pub-id-type="pmcid">PMC4504002</pub-id></element-citation></ref><ref id="B31-vaccines-08-00063"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>Background paper on dengue vaccines</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><fpage>4848</fpage><lpage>4849</lpage></element-citation></ref><ref id="B32-vaccines-08-00063"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarathy</surname><given-names>V.V.</given-names></name><name name-style="western"><surname>Milligan</surname><given-names>G.N.</given-names></name><name name-style="western"><surname>Bourne</surname><given-names>N.</given-names></name><name name-style="western"><surname>Barrett</surname><given-names>A.D.T.</given-names></name></person-group><article-title>Mouse models of dengue virus infection for vaccine testing</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>7051</fpage><lpage>7060</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.09.112</pub-id><pub-id pub-id-type="pmid">26478201</pub-id><pub-id pub-id-type="pmcid">PMC5563257</pub-id></element-citation></ref><ref id="B33-vaccines-08-00063"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ari&#235;n</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Wilder-Smith</surname><given-names>A.</given-names></name></person-group><article-title>Dengue vaccine: Reliably determining previous exposure</article-title><source>Lancet Glob. Health</source><year>2018</year><volume>6</volume><fpage>e830</fpage><lpage>e831</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(18)30295-X</pub-id><pub-id pub-id-type="pmid">29941282</pub-id></element-citation></ref><ref id="B34-vaccines-08-00063"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Durbin</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Kirkpatrick</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Whitehead</surname><given-names>S.S.</given-names></name></person-group><article-title>Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>7242</fpage><lpage>7250</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.07.023</pub-id><pub-id pub-id-type="pmid">21781997</pub-id><pub-id pub-id-type="pmcid">PMC3170437</pub-id></element-citation></ref><ref id="B35-vaccines-08-00063"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lai</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Hori</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bray</surname><given-names>M.</given-names></name></person-group><article-title>Infectious rna transcribed from stably cloned full-length cdna of dengue type 4 virus</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1991</year><volume>88</volume><fpage>5139</fpage><lpage>5143</lpage><pub-id pub-id-type="doi">10.1073/pnas.88.12.5139</pub-id><pub-id pub-id-type="pmid">2052593</pub-id><pub-id pub-id-type="pmcid">PMC51827</pub-id></element-citation></ref><ref id="B36-vaccines-08-00063"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simasathien</surname><given-names>S.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Watanaveeradej</surname><given-names>V.</given-names></name><name name-style="western"><surname>Nisalak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barberousse</surname><given-names>C.</given-names></name><name name-style="western"><surname>Innis</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name><name name-style="western"><surname>Putnak</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Eckels</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Hutagalung</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children</article-title><source>Am. J. Trop. Med. Hyg.</source><year>2008</year><volume>78</volume><fpage>426</fpage><pub-id pub-id-type="doi">10.4269/ajtmh.2008.78.426</pub-id><pub-id pub-id-type="pmid">18337339</pub-id></element-citation></ref><ref id="B37-vaccines-08-00063"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sabchareon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chanthavanich</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yoksan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Forrat</surname><given-names>R.</given-names></name><name name-style="western"><surname>Attanath</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sirivichayakul</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pengsaa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pojjaroen-Anant</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chambonneau</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children</article-title><source>Pediatr. Infect. Dis. J.</source><year>2004</year><volume>23</volume><fpage>99</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1097/01.inf.0000109289.55856.27</pub-id><pub-id pub-id-type="pmid">14872173</pub-id></element-citation></ref><ref id="B38-vaccines-08-00063"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Men</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bray</surname><given-names>M.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chanock</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>C.J.</given-names></name></person-group><article-title>Dengue type 4 virus mutants containing deletions in the 3&#8217; noncoding region of the RNA genome: Analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys</article-title><source>J. Virol.</source><year>1996</year><volume>70</volume><fpage>3930</fpage><lpage>3937</lpage><pub-id pub-id-type="doi">10.1128/JVI.70.6.3930-3937.1996</pub-id><pub-id pub-id-type="pmid">8648730</pub-id><pub-id pub-id-type="pmcid">PMC190271</pub-id></element-citation></ref><ref id="B39-vaccines-08-00063"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Durbin</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Karron</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name><name name-style="western"><surname>Vaughn</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Perreault</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Thumar</surname><given-names>B.</given-names></name><name name-style="western"><surname>Men</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Elkins</surname><given-names>W.R.</given-names></name><etal/></person-group><article-title>Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3&#8217;-untranslated region</article-title><source>Am. J. Trop. Med. Hyg.</source><year>2001</year><volume>65</volume><fpage>405</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.2001.65.405</pub-id><pub-id pub-id-type="pmid">11716091</pub-id></element-citation></ref><ref id="B40-vaccines-08-00063"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Troyer</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Hanley</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Whitehead</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Strickman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Karron</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Durbin</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>B.R.</given-names></name></person-group><article-title>A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes</article-title><source>Am. J. Trop. Med. Hyg.</source><year>2001</year><volume>65</volume><fpage>414</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.2001.65.414</pub-id><pub-id pub-id-type="pmid">11716092</pub-id></element-citation></ref><ref id="B41-vaccines-08-00063"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blaney</surname><given-names>J.E.J.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Firestone</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Hanson</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Whitehead</surname><given-names>S.S.</given-names></name></person-group><article-title>Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice</article-title><source>J. Virol.</source><year>2001</year><volume>75</volume><fpage>9731</fpage><lpage>9740</lpage><pub-id pub-id-type="doi">10.1128/JVI.75.20.9731-9740.2001</pub-id><pub-id pub-id-type="pmid">11559806</pub-id><pub-id pub-id-type="pmcid">PMC114545</pub-id></element-citation></ref><ref id="B42-vaccines-08-00063"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanley</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Blaney</surname><given-names>J.E.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Murphy</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Whitehead</surname><given-names>S.S.</given-names></name></person-group><article-title>Paired charge-to-alanine mutagenesis of dengue virus type 4 ns5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes</article-title><source>J. Virol.</source><year>2001</year><volume>76</volume><fpage>525</fpage><pub-id pub-id-type="doi">10.1128/JVI.76.2.525-531.2002</pub-id><pub-id pub-id-type="pmcid">PMC136841</pub-id><pub-id pub-id-type="pmid">11752143</pub-id></element-citation></ref><ref id="B43-vaccines-08-00063"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanley</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Manlucu</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Manipon</surname><given-names>G.G.</given-names></name><name name-style="western"><surname>Hanson</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Whitehead</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Blaney</surname><given-names>J.E.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Introduction of mutations into the non-structural genes or 3&#8217; untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity</article-title><source>Vaccine</source><year>2004</year><volume>22</volume><fpage>3440</fpage><lpage>3448</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.02.031</pub-id><pub-id pub-id-type="pmid">15308370</pub-id></element-citation></ref><ref id="B44-vaccines-08-00063"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stephen</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Barry</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kathryn</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>E.</given-names></name><name name-style="western"><surname>Blaney</surname><given-names>J.E.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Lewis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brian</surname><given-names>R.M.</given-names></name></person-group><article-title>A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3&#8217; untranslated region is highly attenuated and immunogenic in monkeys</article-title><source>J. Virol.</source><year>2003</year><volume>77</volume><fpage>1653</fpage><lpage>1657</lpage><pub-id pub-id-type="pmid">12502885</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.77.2.1653-1657.2003</pub-id><pub-id pub-id-type="pmcid">PMC140839</pub-id></element-citation></ref><ref id="B45-vaccines-08-00063"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Durbin</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Kirkpatrick</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Elwood</surname><given-names>D.</given-names></name><name name-style="western"><surname>Larsson</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Lindow</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Tibery</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sabundayo</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Shaffer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Talaat</surname><given-names>K.R.</given-names></name><etal/></person-group><article-title>A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: A randomized, double-blind clinical trial</article-title><source>J. Infect. Dis.</source><year>2013</year><volume>207</volume><fpage>957</fpage><lpage>965</lpage><pub-id pub-id-type="doi">10.1093/infdis/jis936</pub-id><pub-id pub-id-type="pmid">23329850</pub-id><pub-id pub-id-type="pmcid">PMC3571448</pub-id></element-citation></ref><ref id="B46-vaccines-08-00063"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirkpatrick</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Durbin</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Carmolli</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Tibery</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Grier</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Hynes</surname><given-names>N.</given-names></name><name name-style="western"><surname>Diehl</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Elwood</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jarvis</surname><given-names>A.P.</given-names></name><etal/></person-group><article-title>Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults</article-title><source>J. Infect. Dis.</source><year>2015</year><volume>212</volume><fpage>702</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiv082</pub-id><pub-id pub-id-type="pmid">25801652</pub-id><pub-id pub-id-type="pmcid">PMC4612392</pub-id></element-citation></ref><ref id="B47-vaccines-08-00063"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirkpatrick</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Whitehead</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Tibery</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Grier</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Hynes</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Larsson</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Sabundayo</surname><given-names>B.P.</given-names></name><name name-style="western"><surname>Talaat</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Janiak</surname><given-names>A.</given-names></name><etal/></person-group><article-title>The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model</article-title><source>Sci. Transl. Med.</source><year>2016</year><volume>8</volume><fpage>330</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aaf1517</pub-id><pub-id pub-id-type="pmid">27089205</pub-id></element-citation></ref><ref id="B48-vaccines-08-00063"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brewoo</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Kinney</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Arguello</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Silengo</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Partidos</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Stinchcomb</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Osorio</surname><given-names>J.E.</given-names></name></person-group><article-title>Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>1513</fpage><lpage>1520</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.11.072</pub-id><pub-id pub-id-type="pmid">22178727</pub-id><pub-id pub-id-type="pmcid">PMC4592107</pub-id></element-citation></ref><ref id="B49-vaccines-08-00063"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Putnak</surname><given-names>R.</given-names></name><name name-style="western"><surname>Barvir</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Burrous</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Dubois</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>D&#8217;Andrea</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Hoke</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Sadoff</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Eckels</surname><given-names>K.H.</given-names></name></person-group><article-title>Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: Immunogenicity and protection in mice and rhesus monkeys</article-title><source>J. Infect. Dis.</source><year>1996</year><volume>174</volume><fpage>1176</fpage><lpage>1184</lpage><pub-id pub-id-type="doi">10.1093/infdis/174.6.1176</pub-id><pub-id pub-id-type="pmid">8940206</pub-id></element-citation></ref><ref id="B50-vaccines-08-00063"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Putnak</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cassidy</surname><given-names>K.</given-names></name><name name-style="western"><surname>Conforti</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sollazzo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Truong</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ing</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dubois</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sparkuhl</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gastle</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Immunogenic and protective response in mice immunized with a purified, inactivated, Dengue-2 virus vaccine prototype made in fetal rhesus lung cells</article-title><source>Am. J. Trop. Med. Hyg.</source><year>1996</year><volume>55</volume><fpage>504</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.1996.55.504</pub-id><pub-id pub-id-type="pmid">8940981</pub-id></element-citation></ref><ref id="B51-vaccines-08-00063"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robert</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Coller</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Voss</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vaughn</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Clements</surname><given-names>D.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bignami</surname><given-names>G.</given-names></name><name name-style="western"><surname>Houng</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Barvir</surname><given-names>D.A.</given-names></name><etal/></person-group><article-title>An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>4442</fpage><lpage>4452</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.03.042</pub-id><pub-id pub-id-type="pmid">16005749</pub-id></element-citation></ref><ref id="B52-vaccines-08-00063"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simmons</surname><given-names>M.</given-names></name><name name-style="western"><surname>Burgess</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lynch</surname><given-names>J.</given-names></name><name name-style="western"><surname>Putnak</surname><given-names>R.</given-names></name></person-group><article-title>Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy</article-title><source>Virology</source><year>2010</year><volume>396</volume><fpage>280</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2009.10.023</pub-id><pub-id pub-id-type="pmid">19913867</pub-id></element-citation></ref><ref id="B53-vaccines-08-00063"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name><name name-style="western"><surname>Nisalak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gettayacamin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eckels</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Putnak</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Vaughn</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Innis</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Endy</surname><given-names>T.P.</given-names></name></person-group><article-title>Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination</article-title><source>Infect. Dis-nor.</source><year>2006</year><volume>193</volume><fpage>1658</fpage><lpage>1665</lpage><pub-id pub-id-type="doi">10.1086/503372</pub-id><pub-id pub-id-type="pmid">16703509</pub-id></element-citation></ref><ref id="B54-vaccines-08-00063"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tripathi</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Shrivastava</surname><given-names>A.</given-names></name></person-group><article-title>Recent Developments in Recombinant Protein-Based Dengue Vaccines</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>1919</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.01919</pub-id><pub-id pub-id-type="pmid">30190720</pub-id><pub-id pub-id-type="pmcid">PMC6115509</pub-id></element-citation></ref><ref id="B55-vaccines-08-00063"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pang</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Loh</surname><given-names>H.S.</given-names></name></person-group><article-title>Towards development of a universal dengue vaccine&#8212;How close are we?</article-title><source>Asian Pac. J. Trop. Med.</source><year>2017</year><volume>10</volume><fpage>220</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/j.apjtm.2017.03.003</pub-id><pub-id pub-id-type="pmid">28442105</pub-id></element-citation></ref><ref id="B56-vaccines-08-00063"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahul</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rajpoot</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Upasana</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ankur</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sathyamangalam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Navin</surname><given-names>K.</given-names></name></person-group><article-title>Pichia pastoris-expressed bivalent virus-like particulate vaccine induces domain iii-focused bivalent neutralizing antibodies without antibody-dependent enhancement in vivo</article-title><source>Front. Microbiol.</source><year>2018</year><volume>8</volume><fpage>2644</fpage><pub-id pub-id-type="pmid">29367852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmicb.2017.02644</pub-id><pub-id pub-id-type="pmcid">PMC5768101</pub-id></element-citation></ref><ref id="B57-vaccines-08-00063"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berlec</surname><given-names>A.</given-names></name><name name-style="western"><surname>&#352;trukelj</surname><given-names>B.</given-names></name></person-group><article-title>Current state and recent advances in biopharmaceutical production in Escherichia coli, yeasts and mammalian cells</article-title><source>J. Ind. Microbiol. Biot.</source><year>2013</year><volume>40</volume><fpage>257</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1007/s10295-013-1235-0</pub-id><pub-id pub-id-type="pmid">23385853</pub-id></element-citation></ref><ref id="B58-vaccines-08-00063"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Babu</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Pattnaik</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shrivastava</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>P.V.L.</given-names></name></person-group><article-title>Immunogenicity of a recombinant envelope domain iii protein of dengue virus type-4 with various adjuvants in mice</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>4655</fpage><lpage>4663</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.07.006</pub-id><pub-id pub-id-type="pmid">18640168</pub-id></element-citation></ref><ref id="B59-vaccines-08-00063"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>X.</given-names></name></person-group><article-title>Eliciting cross-neutralizing antibodies in mice challenged with a dengue virus envelope domain iii expressed in escherichia coli</article-title><source>Can. J. Microbiol.</source><year>2012</year><volume>58</volume><fpage>369</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1139/w11-137</pub-id><pub-id pub-id-type="pmid">22420529</pub-id></element-citation></ref><ref id="B60-vaccines-08-00063"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>60 Chiang</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>P.</given-names></name><name name-style="western"><surname>Leng</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.W.</given-names></name></person-group><article-title>Recombinant lipidated dengue-4 envelope protein domain III elicits protective immunity</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>1346</fpage><lpage>1353</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.01.041</pub-id><pub-id pub-id-type="pmid">24486311</pub-id></element-citation></ref><ref id="B61-vaccines-08-00063"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H.M.</given-names></name><etal/></person-group><article-title>A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates</article-title><source>Arch. Virol.</source><year>2013</year><volume>158</volume><fpage>1523</fpage><lpage>1531</lpage><pub-id pub-id-type="doi">10.1007/s00705-013-1639-1</pub-id><pub-id pub-id-type="pmid">23456422</pub-id></element-citation></ref><ref id="B62-vaccines-08-00063"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiang</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>I.H.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>P.</given-names></name><name name-style="western"><surname>Leng</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.W.</given-names></name></person-group><article-title>Recombinant lipidated dengue-3 envelope protein domain III stimulates broad immune responses in mice</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>1054</fpage><lpage>1061</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.01.009</pub-id><pub-id pub-id-type="pmid">26776472</pub-id></element-citation></ref><ref id="B63-vaccines-08-00063"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiang</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>P.</given-names></name><name name-style="western"><surname>Leng</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.W.</given-names></name></person-group><article-title>Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>30648</fpage><pub-id pub-id-type="doi">10.1038/srep30648</pub-id><pub-id pub-id-type="pmid">27470096</pub-id><pub-id pub-id-type="pmcid">PMC4965760</pub-id></element-citation></ref><ref id="B64-vaccines-08-00063"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lazo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zulueta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hermida</surname><given-names>L.</given-names></name><name name-style="western"><surname>Blanco</surname><given-names>A.</given-names></name><name name-style="western"><surname>S&#225;nchez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vald&#233;s</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gil</surname><given-names>L.</given-names></name><name name-style="western"><surname>L&#243;pez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Romero</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guzm&#225;n</surname><given-names>M.G.</given-names></name><etal/></person-group><article-title>Dengue-4 envelope domain III fused twice within the meningococcal P64k protein carrier induces partial protection in mice</article-title><source>Biotechnol. Appl. Bioc.</source><year>2011</year><volume>52</volume><fpage>265</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1042/BA20080074</pub-id><pub-id pub-id-type="pmid">18636968</pub-id></element-citation></ref><ref id="B65-vaccines-08-00063"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lazo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Izquierdo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Suzarte</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gil</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vald&#233;s</surname><given-names>I.</given-names></name><name name-style="western"><surname>Marcos</surname><given-names>E.</given-names></name><name name-style="western"><surname>&#193;lvarez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Romero</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guzm&#225;n</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Guill&#233;n</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Evaluation in mice of the immunogenicity and protective efficacy of a tetravalent subunit vaccine candidate against dengue virus</article-title><source>Microbiol. Immunol.</source><year>2014</year><volume>58</volume><fpage>219</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1111/1348-0421.12140</pub-id><pub-id pub-id-type="pmid">24689365</pub-id></element-citation></ref><ref id="B66-vaccines-08-00063"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.Z.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>C.F.</given-names></name></person-group><article-title>Induction of Neutralizing Antibodies against Four Serotypes of Dengue Viruses by MixBiEDIII, a Tetravalent Dengue Vaccine</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e86573</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0086573</pub-id><pub-id pub-id-type="pmid">24466156</pub-id><pub-id pub-id-type="pmcid">PMC3897746</pub-id></element-citation></ref><ref id="B67-vaccines-08-00063"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Luong</surname><given-names>N.N.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.</given-names></name><name name-style="western"><surname>Song</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.H.</given-names></name></person-group><article-title>Comparative immunogenicity of preparations of yeast-derived dengue oral vaccine candidate</article-title><source>Microb. Cell Fact.</source><year>2018</year><volume>17</volume><fpage>24</fpage><pub-id pub-id-type="doi">10.1186/s12934-018-0876-0</pub-id><pub-id pub-id-type="pmid">29452594</pub-id><pub-id pub-id-type="pmcid">PMC5815244</pub-id></element-citation></ref><ref id="B68-vaccines-08-00063"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clements</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Coller</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Lieberman</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Ogata</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Harada</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Putnak</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Ivy</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>McDonell</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bignami</surname><given-names>G.S.</given-names></name><etal/></person-group><article-title>Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeys</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>2705</fpage><lpage>2715</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.01.022</pub-id><pub-id pub-id-type="pmid">20097152</pub-id><pub-id pub-id-type="pmcid">PMC2837772</pub-id></element-citation></ref><ref id="B69-vaccines-08-00063"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Govindarajan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Meschino</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Clements</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Ter Meulen</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Casimiro</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Coller</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Bett</surname><given-names>A.J.</given-names></name></person-group><article-title>Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>4105</fpage><lpage>4116</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.06.067</pub-id><pub-id pub-id-type="pmid">26144900</pub-id></element-citation></ref><ref id="B70-vaccines-08-00063"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rantam</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Purwati</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Susilowati</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sudiana</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hendrianto</surname><given-names>E.</given-names></name><collab>Soetjipto</collab></person-group><article-title>Analysis of recombinant, multivalent dengue virus containing envelope (E) proteins from serotypes-1, -3 and -4 and expressed in baculovirus</article-title><source>Trials Vaccinol.</source><year>2015</year><volume>4</volume><fpage>e75</fpage><lpage>e79</lpage></element-citation></ref><ref id="B71-vaccines-08-00063"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>X.</given-names></name></person-group><article-title>Elaboration of tetravalent antibody responses against dengue viruses using a subunit vaccine comprised of a single consensus dengue envelope sequence</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>6308</fpage><lpage>6320</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.09.063</pub-id><pub-id pub-id-type="pmid">28987441</pub-id></element-citation></ref><ref id="B72-vaccines-08-00063"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Van Dolleweerd</surname><given-names>C.</given-names></name><name name-style="western"><surname>Copland</surname><given-names>A.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Hofmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Webster</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Julik</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ceballos-Olvera</surname><given-names>I.</given-names></name><name name-style="western"><surname>Reyes-Del Valle</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.S.</given-names></name><etal/></person-group><article-title>Molecular engineering and plant expression of an immunoglobulin heavy chain scaffold for delivery of a dengue vaccine candidate</article-title><source>Plant Biotechnol. J.</source><year>2017</year><volume>15</volume><fpage>1590</fpage><lpage>1601</lpage><pub-id pub-id-type="pmid">28421694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/pbi.12741</pub-id><pub-id pub-id-type="pmcid">PMC5698049</pub-id></element-citation></ref><ref id="B73-vaccines-08-00063"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.G.</given-names></name></person-group><article-title>Expression of dengue virus e glycoprotein domain iii in non-nicotine transgenic tobacco plants</article-title><source>Biotechnol. Bioproc. Eng.</source><year>2009</year><volume>14</volume><fpage>725</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1007/s12257-009-3011-6</pub-id></element-citation></ref><ref id="B74-vaccines-08-00063"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>B.Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.Y.</given-names></name></person-group><article-title>Evaluation of the oral immunogenicity of M cell-targeted tetravalent EDIII antigen for development of plant-based edible vaccine against dengue infection</article-title><source>Plant Cell Tiss. Org.</source><year>2019</year><volume>137</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1007/s11240-018-01544-9</pub-id></element-citation></ref><ref id="B75-vaccines-08-00063"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Prince</surname><given-names>G.</given-names></name><name name-style="western"><surname>Horswood</surname><given-names>R.</given-names></name><name name-style="western"><surname>Eckels</surname><given-names>K.</given-names></name><name name-style="western"><surname>Summers</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chanock</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>C.J.</given-names></name></person-group><article-title>Expression of dengue virus structural proteins and nonstructural protein NS1 by a recombinant vaccinia virus</article-title><source>J. Virol.</source><year>1987</year><volume>61</volume><fpage>4019</fpage><lpage>4022</lpage><pub-id pub-id-type="doi">10.1128/JVI.61.12.4019-4022.1987</pub-id><pub-id pub-id-type="pmid">3316711</pub-id><pub-id pub-id-type="pmcid">PMC256024</pub-id></element-citation></ref><ref id="B76-vaccines-08-00063"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Men</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Bray</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>C.J.</given-names></name></person-group><article-title>Carboxy-terminally truncated dengue virus envelope glycoproteins expressed on the cell surface and secreted extracellularly exhibit increased immunogenicity in mice</article-title><source>J. Virol.</source><year>1991</year><volume>65</volume><fpage>1400</fpage><lpage>1407</lpage><pub-id pub-id-type="doi">10.1128/JVI.65.3.1400-1407.1991</pub-id><pub-id pub-id-type="pmid">1995950</pub-id><pub-id pub-id-type="pmcid">PMC239918</pub-id></element-citation></ref><ref id="B77-vaccines-08-00063"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bray</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Markoff</surname><given-names>L.</given-names></name><name name-style="western"><surname>Eckels</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Chanock</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>C.J.</given-names></name></person-group><article-title>Mice immunized with recombinant vaccinia virus expressing dengue 4 virus structural proteins with or without nonstructural protein ns1 are protected against fatal dengue virus encephalitis</article-title><source>J. Virol.</source><year>1989</year><volume>63</volume><fpage>2853</fpage><lpage>2856</lpage><pub-id pub-id-type="doi">10.1128/JVI.63.6.2853-2856.1989</pub-id><pub-id pub-id-type="pmid">2724416</pub-id><pub-id pub-id-type="pmcid">PMC250798</pub-id></element-citation></ref><ref id="B78-vaccines-08-00063"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>McCarty</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Dubois</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Summers</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Eckels</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Chanock</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>C.J.</given-names></name></person-group><article-title>Immunization of mice with dengue structural proteins and nonstructural protein NS1 expressed by baculovirus recombinant induces resistance to dengue virus encephalitis</article-title><source>J. Virol.</source><year>1988</year><volume>62</volume><fpage>3027</fpage><pub-id pub-id-type="doi">10.1128/JVI.62.8.3027-3031.1988</pub-id><pub-id pub-id-type="pmid">2969058</pub-id><pub-id pub-id-type="pmcid">PMC253742</pub-id></element-citation></ref><ref id="B79-vaccines-08-00063"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Men</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wyatt</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tokimatsu</surname><given-names>I.</given-names></name><name name-style="western"><surname>Arakaki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shameem</surname><given-names>G.</given-names></name><name name-style="western"><surname>Elkins</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chanock</surname><given-names>R.</given-names></name><name name-style="western"><surname>Moss</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>C.J.</given-names></name></person-group><article-title>Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge</article-title><source>Vaccine</source><year>2000</year><volume>18</volume><fpage>3113</fpage><lpage>3122</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(00)00121-3</pub-id><pub-id pub-id-type="pmid">10856791</pub-id></element-citation></ref><ref id="B80-vaccines-08-00063"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andrea</surname><given-names>A.</given-names></name><name name-style="western"><surname>Albright</surname><given-names>E.D.</given-names></name></person-group><article-title>Genetics:molecular therapy: The journal of the american society of gene therapy</article-title><source>Jama-J. Am. Med. Assoc.</source><year>2003</year><volume>289</volume><fpage>622</fpage></element-citation></ref><ref id="B81-vaccines-08-00063"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smita</surname><given-names>J.</given-names></name><name name-style="western"><surname>Navin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Swaminathan</surname><given-names>S.</given-names></name></person-group><article-title>Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2</article-title><source>J. Virol.</source><year>2003</year><volume>77</volume><fpage>12907</fpage><pub-id pub-id-type="pmid">14610213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.77.23.12907-12913.2003</pub-id><pub-id pub-id-type="pmcid">PMC262593</pub-id></element-citation></ref><ref id="B82-vaccines-08-00063"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khanam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rajendra</surname><given-names>P.</given-names></name><name name-style="western"><surname>Khanna</surname><given-names>N.</given-names></name><name name-style="western"><surname>Swaminathan</surname><given-names>S.</given-names></name></person-group><article-title>An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes</article-title><source>BMC Biotechnol.</source><year>2007</year><volume>7</volume><elocation-id>10</elocation-id><pub-id pub-id-type="doi">10.1186/1472-6750-7-10</pub-id><pub-id pub-id-type="pmid">17302980</pub-id><pub-id pub-id-type="pmcid">PMC1805746</pub-id></element-citation></ref><ref id="B83-vaccines-08-00063"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khanam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pilankatta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Khanna</surname><given-names>N.</given-names></name><name name-style="western"><surname>Swaminathan</surname><given-names>S.</given-names></name></person-group><article-title>An adenovirus type 5 (adv5) vector encoding an envelope domain iii-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior adv5 immunity</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>6011</fpage><lpage>6021</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.07.073</pub-id><pub-id pub-id-type="pmid">19665609</pub-id></element-citation></ref><ref id="B84-vaccines-08-00063"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holman</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Raviprakash</surname><given-names>K.</given-names></name><name name-style="western"><surname>Raja</surname><given-names>N.U.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>J.Y.</given-names></name></person-group><article-title>Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes</article-title><source>Clin. Vaccine Immunol.</source><year>2007</year><volume>14</volume><fpage>182</fpage><pub-id pub-id-type="doi">10.1128/CVI.00330-06</pub-id><pub-id pub-id-type="pmid">17192403</pub-id><pub-id pub-id-type="pmcid">PMC1797786</pub-id></element-citation></ref><ref id="B85-vaccines-08-00063"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raviprakash</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ewing</surname><given-names>D.</given-names></name><name name-style="western"><surname>Holman</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Block</surname><given-names>K.</given-names></name><name name-style="western"><surname>Woraratanadharm</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>K.</given-names></name></person-group><article-title>A Tetravalent Dengue Vaccine Based on a Complex Adenovirus Vector Provides Significant Protection in Rhesus Monkeys against All Four Serotypes of Dengue Virus</article-title><source>J. Virol.</source><year>2008</year><volume>82</volume><fpage>6927</fpage><pub-id pub-id-type="doi">10.1128/JVI.02724-07</pub-id><pub-id pub-id-type="pmid">18480438</pub-id><pub-id pub-id-type="pmcid">PMC2446963</pub-id></element-citation></ref><ref id="B86-vaccines-08-00063"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macdonald</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>R.E.</given-names></name></person-group><article-title>Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis</article-title><source>J. Virol.</source><year>2000</year><volume>74</volume><fpage>914</fpage><lpage>922</lpage><pub-id pub-id-type="doi">10.1128/JVI.74.2.914-922.2000</pub-id><pub-id pub-id-type="pmid">10623754</pub-id><pub-id pub-id-type="pmcid">PMC111612</pub-id></element-citation></ref><ref id="B87-vaccines-08-00063"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Whitmore</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Konopka</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Collier</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>R.E.</given-names></name></person-group><article-title>Mucosal and systemic adjuvant activity of alphavirus replicon particles</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2006</year><volume>103</volume><fpage>3722</fpage><lpage>3727</lpage><pub-id pub-id-type="doi">10.1073/pnas.0600287103</pub-id><pub-id pub-id-type="pmid">16505353</pub-id><pub-id pub-id-type="pmcid">PMC1383499</pub-id></element-citation></ref><ref id="B88-vaccines-08-00063"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ewing</surname><given-names>D.</given-names></name><name name-style="western"><surname>Subramanian</surname><given-names>H.</given-names></name><name name-style="western"><surname>Block</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rayner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Alterson</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Sedegah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>K.</given-names></name><name name-style="western"><surname>Raviprakash</surname><given-names>K.</given-names></name></person-group><article-title>A heterologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques</article-title><source>J. Virol.</source><year>2007</year><volume>81</volume><fpage>11634</fpage><pub-id pub-id-type="pmid">17715224</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.00996-07</pub-id><pub-id pub-id-type="pmcid">PMC2168814</pub-id></element-citation></ref><ref id="B89-vaccines-08-00063"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Sariol</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Mattocks</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Wahala</surname><given-names>M.P.B.W.</given-names></name><name name-style="western"><surname>Yingsiwaphat</surname><given-names>V.</given-names></name><name name-style="western"><surname>Collier</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Whitley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mikkelsen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>I.V.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>M.I.</given-names></name><etal/></person-group><article-title>An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>3409</fpage><lpage>3424</lpage><pub-id pub-id-type="pmid">23302884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02298-12</pub-id><pub-id pub-id-type="pmcid">PMC3592161</pub-id></element-citation></ref><ref id="B90-vaccines-08-00063"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalil</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Tonkin</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Mattocks</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Snead</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>White</surname><given-names>L.J.</given-names></name></person-group><article-title>A tetravalent alphavirus-vector based dengue vaccine provides effective immunity in an early life mouse model</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>4068</fpage><lpage>4074</lpage><pub-id pub-id-type="pmid">24882043</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2014.05.053</pub-id><pub-id pub-id-type="pmcid">PMC4487803</pub-id></element-citation></ref><ref id="B91-vaccines-08-00063"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kochel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Raviprakash</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hobart</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>C.</given-names></name></person-group><article-title>Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice</article-title><source>Vaccine</source><year>1997</year><volume>15</volume><fpage>547</fpage><pub-id pub-id-type="doi">10.1016/S0264-410X(97)00215-6</pub-id><pub-id pub-id-type="pmid">9160523</pub-id></element-citation></ref><ref id="B92-vaccines-08-00063"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raviprakash</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kochel</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Ewing</surname><given-names>D.</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>M.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>K.R.</given-names></name></person-group><article-title>Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein</article-title><source>Vaccine</source><year>2000</year><volume>18</volume><fpage>2426</fpage><lpage>2434</lpage><pub-id pub-id-type="pmid">10738100</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0264-410x(99)00570-8</pub-id></element-citation></ref><ref id="B93-vaccines-08-00063"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kochel</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Raviprakash</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Watts</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Russell</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Gozalo</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Ewing</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>K.R.</given-names></name></person-group><article-title>A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys</article-title><source>Vaccine</source><year>2000</year><volume>18</volume><fpage>3166</fpage><lpage>3173</lpage><pub-id pub-id-type="pmid">10856796</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0264-410x(00)00105-5</pub-id></element-citation></ref><ref id="B94-vaccines-08-00063"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beckett</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Tjaden</surname><given-names>J.</given-names></name><name name-style="western"><surname>Burgess</surname><given-names>T.</given-names></name><name name-style="western"><surname>Danko</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Tamminga</surname><given-names>C.</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kochel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Raviprakash</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>960</fpage><lpage>968</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.11.050</pub-id><pub-id pub-id-type="pmid">21111785</pub-id></element-citation></ref><ref id="B95-vaccines-08-00063"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Porter</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Kochel</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Raviprakash</surname><given-names>K.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>C.G.</given-names></name></person-group><article-title>Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses</article-title><source>Arch. Virol.</source><year>1998</year><volume>143</volume><fpage>997</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1007/s007050050348</pub-id><pub-id pub-id-type="pmid">9645204</pub-id></element-citation></ref><ref id="B96-vaccines-08-00063"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simmons</surname><given-names>M.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Kochel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Raviprakash</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>C.G.</given-names></name></person-group><article-title>Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine</article-title><source>Am. J. Trop. Med. Hyg.</source><year>2001</year><volume>65</volume><fpage>420</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.2001.65.420</pub-id><pub-id pub-id-type="pmid">11716093</pub-id></element-citation></ref><ref id="B97-vaccines-08-00063"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simmons</surname><given-names>M.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Vaughn</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Putnak</surname><given-names>R.</given-names></name></person-group><article-title>Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques</article-title><source>J. Virol.</source><year>2006</year><volume>80</volume><fpage>9577</fpage><lpage>9585</lpage><pub-id pub-id-type="doi">10.1128/JVI.00284-06</pub-id><pub-id pub-id-type="pmid">16973561</pub-id><pub-id pub-id-type="pmcid">PMC1617260</pub-id></element-citation></ref><ref id="B98-vaccines-08-00063"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raviprakash</surname><given-names>K.</given-names></name><name name-style="western"><surname>Marques</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ewing</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>I.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Kochel</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>August</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>G.S.</given-names></name></person-group><article-title>Synergistic Neutralizing Antibody Response to a Dengue Virus Type 2 DNA Vaccine by Incorporation of Lysosome-Associated Membrane Protein Sequences and Use of Plasmid Expressing GM-CSF</article-title><source>Virology</source><year>2001</year><volume>290</volume><fpage>74</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1006/viro.2001.1136</pub-id><pub-id pub-id-type="pmid">11883007</pub-id></element-citation></ref><ref id="B99-vaccines-08-00063"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zaneti</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Sulczewski</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>B.D.S.</given-names></name><name name-style="western"><surname>Souza</surname><given-names>H.F.S.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Maeda</surname><given-names>D.L.N.F.</given-names></name><name name-style="western"><surname>Sales</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Rosa</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>L.C.S.</given-names></name><etal/></person-group><article-title>Dendritic Cell Targeting Using a DNA Vaccine Induces Specific Antibodies and CD4(+) T Cells to the Dengue Virus Envelope Protein Domain III</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>59</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.00059</pub-id><pub-id pub-id-type="pmid">30761131</pub-id><pub-id pub-id-type="pmcid">PMC6362411</pub-id></element-citation></ref><ref id="B100-vaccines-08-00063"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Danko</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Kochel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Teneza-Mora</surname><given-names>N.</given-names></name><name name-style="western"><surname>Luke</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Raviprakash</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>P.</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>De La Barrera</surname><given-names>R.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>L.J.</given-names></name><etal/></person-group><article-title>Safety and Immunogenicity of a Tetravalent Dengue DNA Vaccine Administered with a Cationic Lipid-Based Adjuvant in a Phase 1 Clinical Trial</article-title><source>Am. J. Trop. Med. Hyg.</source><year>2018</year><volume>98</volume><fpage>849</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.17-0416</pub-id><pub-id pub-id-type="pmid">29363446</pub-id><pub-id pub-id-type="pmcid">PMC5930886</pub-id></element-citation></ref><ref id="B101-vaccines-08-00063"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Danko</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Beckett</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>K.R.</given-names></name></person-group><article-title>Development of dengue dna vaccines</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>7261</fpage><lpage>7266</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.07.019</pub-id><pub-id pub-id-type="pmid">21777640</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="vaccines-08-00063-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">vaccines-08-00063-t001_Table 1</object-id><label>Table 1</label><caption><p>Dengue vaccine candidates in use or in clinical trials.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Strategy</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Trial Phase</th></tr></thead><tbody><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Live Attenuated vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CYD-TDV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Replacing the prM/E gene of the YF17D virus with genes of the DENV1&#8211;4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Evaluation after part of the license</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TV003/TV005</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Attenuation by truncating 30 nucleotides in the 3&#8242; UTR of DENV1, DENV3, DENV4, and a chimeric DENV2/DENV4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase III</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DENVax</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Replacing the coding sequences of DENV2 PDK-53 attenuated vaccine with that of DENV1, DENV3, and DENV4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase III</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PIV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Purified formalin-inactivated virus and adjuvants</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V180</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A recombinant truncated protein containing DEN-80E</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DNA vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">D1ME100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombinant plasmid vector encoding prM/E </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TVDV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recombinant plasmid vector encoding prM/E proteins of DENV1&#8211;4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Heterologous prime/boost</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TLAV Prime/PIV boost and reverse order</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Initial immune-boost strategy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase I</td></tr></tbody></table><table-wrap-foot><fn><p>CYD-TDV: the live attenuated chimeric yellow fever 17D virus-tetravalent dengue vaccine; DENVax: the live attenuated tetravalent dengue vaccine; PIV: the purified formalin-inactivated virus vaccine; TVDV: the tetravalent DNA vaccine; TLAV: the tetra-live attenuated virus vaccine.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>